Loading stock data…
Orthofix Medical Inc. (OFIX)
$11.25+0.29 (+2.65%)
Market ClosedLast close Jul 24
Orthofix Medical Inc., together with its subsidiaries, operates as a medical technology company in the United States, Italy, the United Kingdom, France, Germany, Brazil, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Orthofix Medical Inc. in the Healthcare sector is trading at $11.25 with a market capitalization of $393M. Wall Street consensus targets $15.50 (4 analysts), implying a +37.8% move over the next 12 months. The stock is currently 34% below its 52-week high of $16.99, remaining 13.5% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +37.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $196.71M↓ | $219.91M↑ | $205.63M↑ | $203.12M↑ | $193.65M |
| Gross Profit | $139.55M↓ | $156.34M↑ | $148.52M↑ | $139.53M↑ | $121.62M |
| Operating Income | -$13.69M↓ | $1.15M↑ | -$17.47M↓ | -$16.77M↑ | -$49.48M |
| Net Income | -$20.91M↓ | -$2.22M↑ | -$22.80M↓ | -$14.08M↑ | -$53.09M |
Peer Comparison
JNJUNHPFE
Fundamentals
Orthofix Medical Inc., together with its subsidiaries, operates as a medical technology company in the United States, Italy, the United Kingdom, France, Germany, Brazil, and internationally. It operates through two segments, Global Spine and Global L...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$392.90M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.79
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-13.79%
Volume
Today's trading volume
226,011
Recent News
Orthofix Medical (OFIX) Looks Attractive After CMS Reversed Its Reimbursement
Rewey Asset Management, an investment management firm, released its “RAM Smid Composite” investor letter for the second quarter of 2026. A copy of the letter can be downloaded here. Rewey Asset Management, an investment management firm, released its “RAM Smid Composite” investor letter for the second quarter of 2026. RAM Smid Composite gained 20.06% in the […]
Wall Street Analysts Think Orthofix (OFIX) Could Surge 33.28%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 33.3% in Orthofix (OFIX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Orthofix Medical (OFIX) Among the Best Small-Cap Growth Stocks To Buy Now
Orthofix Medical Inc. (NASDAQ:OFIX) is one of the Best Small-Cap Growth Stocks to Invest In Now. The stock has declined roughly 22% since its fiscal Q1 2026 earnings. Despite the softness, the Street remains bullish, with analysts’ 12-month price target suggesting more than 54% upside from the current level. Orthofix Medical Inc. (NASDAQ:OFIX) released earnings […]
Orthofix (OFIX) Moves 5.1% Higher: Will This Strength Last?
Orthofix (OFIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Orthofix Medical (OFIX) Stock Sees Split Analyst Revisions After CMS Reimbursement Reset
The latest analyst update on Orthofix Medical keeps the model fair value steady at US$15.0 per share, signaling no reset to the core price target despite refreshed assumptions. This stable fair value sits against a backdrop of mixed analyst commentary, with some focusing on the reset in reimbursement expectations for non invasive bone growth stimulators and others stressing the earnings headwind from the new CMS framework. As you read on, you will see how these shifting views shape the...